- Enrolling by invitation
Long-Term Follow-up of Subjects Who Were Treated With ST-920
This study is checking on the long-term effects of an investigational medicine called ST-920, used for Fabry disease. It follows people who received ST-920 in an earlier trial, monitoring their health for up to five years after treatment.
For: Fabry Disease · Fabry Disease, Cardiac VariantUnited States · Australia · Canada - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease.
This study is testing a new gene therapy, ST-920, for men with Fabry disease. It's an early-stage trial looking at how safe the treatment is and if it helps by correcting the faulty gene causing the condition. Researchers will carefully check participants' health.
For: Fabry Disease (X-linked lysosomal storage disease).Italy · Germany